EP3624853A1 - Freisetzung von wirkstoffen unter verwendung siliconhaltiger polymere - Google Patents
Freisetzung von wirkstoffen unter verwendung siliconhaltiger polymereInfo
- Publication number
- EP3624853A1 EP3624853A1 EP17724792.1A EP17724792A EP3624853A1 EP 3624853 A1 EP3624853 A1 EP 3624853A1 EP 17724792 A EP17724792 A EP 17724792A EP 3624853 A1 EP3624853 A1 EP 3624853A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- active substance
- silicone
- general formula
- hydrogen
- groups
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L83/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon only; Compositions of derivatives of such polymers
- C08L83/04—Polysiloxanes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L83/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon only; Compositions of derivatives of such polymers
- C08L83/04—Polysiloxanes
- C08L83/08—Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen and oxygen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
- C08G77/04—Polysiloxanes
- C08G77/22—Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen and oxygen
- C08G77/26—Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen and oxygen nitrogen-containing groups
Definitions
- the invention relates to an active substance (W) for use in a process for the release of active substance (W), in which a shaped body (F) comprising a composition (Z) which comprises silicone-containing polymer (P) and active substance (W) .
- composition (Z) is added with water, whereby the composition (Z)
- Active ingredient (W) releases the shaped body (F) and a process for producing the shaped bodies (F).
- Active ingredients are used in various fields, in particular in medicine and pharmacy, in cosmetics, in agriculture or in biotechnology.
- polymeric materials from which the active ingredient may be set free ⁇ are used iA polymeric materials from which the active ingredient may be set free ⁇ . It is often desirable here that the controlled release of the active ingredients by contact with moist or aqueous media takes place, for example for agricultural applications in soils, in pharmacy and medicine in the body by contact with body fluid or on the skin surface by sweat.
- the release of the active ingredient is based on a permeability of the polymer to water in a moist or aqueous environment (for a review, see R. Po, J. Macromolec Sc, C, Rev. Macromol, Chem. Phys., C34, p. 650, 1994).
- Examples of polymers used are carboxymethylcellulose or copolymers of sodium acrylate and starch.
- a disadvantage of these polymer materials, however, is that they gradually dissolve during the swelling process. It would therefore be desirable to have a largely water-insoluble material which does not have the disadvantages mentioned.
- Silicone-based polymers have hitherto been used singly as matrices for drugs. Advantages of silicone-containing polymers are their high biocompatibility, their chemical properties
- Silicone-containing polymers also have the advantage that they have only low brittleness and optionally plastically deformable, which is particularly advantageous for applications on the skin. In these applications, an increased gas permeability may be desirable, for which silicone-containing polymers
- Materials are particularly suitable because of their high gas permeability.
- 2013/0172419 was also shown that a drug release from pure silicone materials is not carried out to any significant extent.
- the invention relates to an active substance (W) for use in a process for the release of active ingredient (W), in which a shaped body (F) containing a composition (Z), which silicone-containing polymer (P) and active ingredient (W) includes, is added with water, whereby the composition releases (Z) active ingredient (W),
- silicone-containing polymer (P) at least one siloxane unit of the general formula I and no or at least one unit of the general formula II
- R 1 and R 2 are independently hydrogen or a straight, branched or cyclic saturated or unsaturated ⁇ saturated alkyl group having 1 to 20 carbon atoms or aryl group or aralkyl group, wherein individual non-adjacent Me ⁇ thylenechen by groups -0-, -CO-, -COO-, -OCO- or -OCOO-, -S- or NR X or may be replaced by an oxyalkylene group of the general formula (-O-CH 2 -CHR 3 -) d,
- R 3 is hydrogen or alkyl
- R X is hydrogen or an unsubstituted or ducks with substitution selected from -CN and halogen substi ⁇ -substituted C 1 -C 1 0 - hydrocarbon radical,
- X is a radical of the general formula which carries at least one amino acid unit and is bonded via a carbon atom to the silicon atom
- M is hydrogen, metal or an ammonium radical NR 10 4 + ,
- R 10 is independently hydrogen or C 1 -C 1 2 alkyl, aryl or aralkyl
- R 4 is hydrogen or a linear, branched or cyclic saturated or unsaturated alkyl group having 1 to 20 C atoms or aryl group or aralkyl group, where individual non-adjacent methylene units are represented by groups -O-, -CO-, -COO-, -OCO- or - OCOO-, -S- or NR X or may be replaced by an oxyalkylene group of the general formula (-O-CH 2 -CHR 3 -) d,
- R 5 and R 6 are independently hydrogen or linear
- Y is a linear, branched, cyclic, saturated or mono- or polyunsaturated C 1 to C 100 alkylene radical connected via a carbon atom to the organosilicon compound, in which individual carbon atoms may be replaced by oxygen, nitrogen or sulfur atoms,
- a 0, 1, 2 or 3
- c 1, 2 or 3
- e have integer values 0 to 50.
- the subject of the invention is also a shaped body (F),
- composition (Z) comprising the silicone-containing polymer (P) and the active ingredient (W).
- silicone-containing polymers (P) are silicone-containing polymers (P)
- the silicone-containing polymer (P) is preferably solid at 20 ° C and 1 bar.
- the silicone-containing polymer (P) is solid in the range of -10 ° C to 50 ° C and 1 bar.
- amino acid moieties -Y-NR 4 - (CH 2 ) e -CR 5 R 6 -COOM can exist in different protonation states.
- Carboxylic acid groups may be present as a free carboxylic acid or as a carboxylate salt or as mixtures of these.
- the amino moiety may be present both as a free amino group or in protonated form as an ammonium moiety or as a mixture thereof.
- R 1 and R 2 independently of one another preferably denote hydrogen or an unbranched, branched or cyclic saturated or unsaturated alkyl group having 1 to 6 C atoms or a benzyl or phenyl group, where non-adjacent methylene units may be replaced by nitrogen atoms or oxygen atoms, or may be replaced by an oxyalkylene group of the general formula (-O-CH 2 -CHR 3 -) d .
- R 3 is hydrogen or methyl, in particular
- R x is preferably hydrogen or an unsubstituted C 1 -C 6 -hydrocarbon radical.
- M is preferably hydrogen, alkali metal or
- Alkaline earth metal particularly preferably alkali metal, particularly particularly preferably sodium or potassium, or a
- R 10 is hydrogen or C 1 -C 4 alkyl.
- R 4 is preferably hydrogen or a linear, branched or cyclic saturated or unsaturated alkyl group having 1 to 10 carbon atoms or a benzyl or phenyl group, wherein non-adjacent methylene units may be replaced by nitrogen atoms or oxygen atoms, or by a
- Formula -0- (CH 2 -CHR 3 -) d may be substituted, especially methyl.
- the radicals R 3 mean hydrogen or
- Methyl especially methyl.
- R 5 is hydrogen and R 6 is hydrogen or a linear, branched or cyclic saturated or unsaturated alkyl group having 1 to 10 C atoms or aryl group or
- Aralkyl group wherein individual non-adjacent methylene units can be replaced by groups -0-, -CO-, -COO-, -OCO- or -OCOO-, -S- or NR X.
- R 5 is hydrogen and R 6 is hydrogen or
- radicals are preferably linked via an alkylene radical, in particular with 1 to 6 carbon atoms.
- Y is preferably a linear or branched, saturated C 1 to C 20 alkylene radical in which individual carbon atoms can be replaced by oxygen, nitrogen or sulfur atoms.
- Y is particularly preferably a grouping
- Z is preferably a bonded via a carbon atom of the organosilicon compound with the linear, branched, cyclic, saturated or mono- or polyunsaturated C to C alkylene group 100, may be at the individual coals ⁇ atoms replaced by oxygen atoms.
- Z is particularly preferably an oxyalkylene radical of the general formula
- radicals R 11 independently of one another are hydrogen or alkyl, in particular methyl
- f has a value of 0 to 100, preferably 0 to 50 and particularly preferably 0.
- the radicals R 7, R 8 and R 9 are independently hydrogen or a linear Ci to Ce alkyl group, particularly preferably hydrogen or linear Ci to C3 alkyl group.
- the radicals R and R can also be via alkylene radicals or oxygen be connected with each other and with the grouping Z.
- d and f are each independently of one another preferably 0 to 50, particularly preferably 0 to 10, particularly preferably 0 to 5 and very particularly preferably the values 0 to 3.
- e is preferably 0 to 10, particularly preferably 0 to 5 and very particularly preferably 0 to 3.
- silicone polymers (P) can be prepared in a manner known to those skilled in the art. For example, the following reactions can be used for the attachment of the amino acids to the silicone:
- Amino group may be bound to two silicone radicals. Contains one amino acid more than one basic nitrogen-containing one
- siloxane or the amino acid units to each other may be different.
- the silicone-containing polymers (P) used to release active ingredients (W) may contain other polymers. These may form homogeneous or inhomogeneous mixtures, they may be covalently linked to the polymer (P) or via H-bonds or they may be unbonded.
- the silicone-containing polymers (P) contain these other polymers preferably in
- the silicone-containing polymer (P) may comprise blocks of siloxane units of the general formula I and none or at least one unit of the general formula II and organic blocks which interrupt the blocks of siloxane units.
- the organic blocks may be connected to the blocks of siloxane units, for example via urea groups, urethane groups or ester groups.
- the proportion of organic blocks is preferably at least 2 and at most 300 parts by weight, more preferably at most 30 parts by weight, in particular at most 10 parts by weight per 100 parts by weight of siloxane units of the general formulas I and I I.
- the polymers (P) used for controlled release of active substances (W) may be crosslinked or uncrosslinked.
- composition (Z) may contain other substances which are present either as solids or dissolved.
- fillers such as finely divided silica, silicates, zeolites or carbon ⁇ based fillers, such as carbon black are used.
- the composition (Z) may also contain liquids or liquid mixtures as additives. These components can accelerate or reduce the release of the active ingredient (W).
- the proportion of liquid additives is preferably at least 0.01 and not more than 1000 parts by weight, more preferably at least 0.1 and not more than 100 parts by weight, especially at least 1 and at most 10 weight parts per 100 weight parts ⁇ siloxane units of the general formulas I and II.
- Preferred liquid additives are water, organic liquid ⁇ speeds or mixtures thereof, for example, other siloxanes, esters, mono- or polyhydric alcohols, ethers, hydrocarbons.
- composition (Z) for example, by contacting the composition (Z) with wet materials and surfaces or aqueous
- composition (Z) and water-containing medium further layers may be present in the shaped body (F), which allow the transport of water in either liquid or gaseous form.
- the transport of water in liquid or gaseous form through these layers can be via pores or via channels.
- Shaped bodies (F) can be granules, sticks,
- Leaflets, films, cavities containing materials e.g.
- active ingredients (W) are preferably substances which have an effect on biological systems.
- drugs active pharmaceutical ingredients
- drugs active pharmaceutical ingredients
- Hormones vitamins, trace elements, pesticides, and others.
- Pheromones phytohormones, fragrances, enzymes, coenzymes or antibodies, chelating agents, metals or metal ions,
- Light absorbers antioxidants and pigments.
- the production of the shaped bodies (F) can be carried out, for example, by adding a solution of the polymer (P) with the active ingredient (W) in the desired amount and preferably evaporating the resulting mixture subsequently. This results in the composition (Z).
- Another possibility is to contact shaped bodies (F) containing the polymer (P) with liquid, for example water, or with a water-containing mixture which contains the active ingredient (W).
- liquid for example water
- W active ingredient
- the active ingredient (W) can diffuse from the liquid into the polymer (P) in this way. This also produces the composition (Z).
- the solid composition (Z) may after evaporation or contact with liquid
- the solution of the polymer (P) with the active ingredient (W) can also be placed in molds and evaporated.
- the release of active ingredient (W) is preferably carried out in
- the release of active ingredient (W) is preferably carried out at
- the release of active ingredient (W) is preferably carried out at a pressure of at least 0.1 mbar to at most 50 bar, more preferably at least 100 mbar to at most 20 bar, particularly preferably at least 0.9 bar to 10 bar.
- the release of active ingredient (W) can also be controlled by the pH or the change in the pH or electrically by changing the potential.
- a terminal glycidoxypropyl-functionalized silicone polymer having a molecular weight of about 900 are dissolved in 75 ml of methanol and added at reflux temperature to a solution of 10 g of lysine in 260 g of methanol. The mixture is refluxed for 9 hours, filtered and the clear polymer solution is concentrated to a solids content of about 40 ⁇ 6.
- Example 2 introduction of the active ingredient (W) into the polymer matrix
- W active ingredient
- Example 2 introduction of the active ingredient (W) into the polymer matrix
- 352 mg of nicotinic acid are dissolved.
- the drug-containing polymer solution is poured into a Teflon mold.
- a clear nicotinic acid-containing polymer film receive .
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Silicon Polymers (AREA)
Abstract
Description
Claims
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2017/061696 WO2018210406A1 (de) | 2017-05-16 | 2017-05-16 | Freisetzung von wirkstoffen unter verwendung siliconhaltiger polymere |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3624853A1 true EP3624853A1 (de) | 2020-03-25 |
Family
ID=58745215
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17724792.1A Withdrawn EP3624853A1 (de) | 2017-05-16 | 2017-05-16 | Freisetzung von wirkstoffen unter verwendung siliconhaltiger polymere |
Country Status (5)
Country | Link |
---|---|
US (1) | US20230099877A1 (de) |
EP (1) | EP3624853A1 (de) |
KR (1) | KR20190132542A (de) |
CN (1) | CN110636864A (de) |
WO (1) | WO2018210406A1 (de) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5272241A (en) * | 1992-08-21 | 1993-12-21 | General Electric Company | Amino acid functionalized silicones and method for preparation |
US8772422B2 (en) | 2012-01-04 | 2014-07-08 | Momentive Performance Materials Inc. | Polymer composites of silicone ionomers |
DE102013214081A1 (de) * | 2013-07-18 | 2015-01-22 | Evonik Industries Ag | Neue aminosäuremodifizierte Siloxane, Verfahren zu ihrer Herstellung und Anwendung |
DE102015210173A1 (de) * | 2015-06-02 | 2016-12-08 | Wacker Chemie Ag | Verfahren zur Herstellung von Aminosäure-Gruppierungen aufweisenden Organosiliciumverbindungen |
-
2017
- 2017-05-16 WO PCT/EP2017/061696 patent/WO2018210406A1/de unknown
- 2017-05-16 KR KR1020197033589A patent/KR20190132542A/ko not_active Application Discontinuation
- 2017-05-16 CN CN201780090847.5A patent/CN110636864A/zh not_active Withdrawn
- 2017-05-16 EP EP17724792.1A patent/EP3624853A1/de not_active Withdrawn
- 2017-05-16 US US16/613,883 patent/US20230099877A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20230099877A1 (en) | 2023-03-30 |
WO2018210406A1 (de) | 2018-11-22 |
KR20190132542A (ko) | 2019-11-27 |
CN110636864A (zh) | 2019-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60200416T2 (de) | Kombination von Carbidopa und Levodopa mit verzögerter Wirkstoffabgabe | |
DE60126433T2 (de) | Prozess zur herstellung von pharmazeutischen zusammensetzungen zur verwendung mit weichgelatine formulierungen | |
EP0164669A2 (de) | Verfahren zum Überziehen von Arzneiformen | |
DE3241097A1 (de) | Medikamente mit hohem loeslichkeitsgrad und verfahren zu ihrer herstellung | |
DE3320582A1 (de) | Gliquidonhaltige zubereitungsformen und verfahren zu ihrer herstellung | |
DE1720955B2 (de) | Verfahren zur Herstellung eines polymeren Formgegenstands mit gegenüber Proteinen reaktionsfähigen Gruppen auf seiner Oberfläche | |
WO2007073932A2 (de) | Proteinbasiertes trägersystem zur resistenzüberwindung von tumorzellen | |
WO2017133868A1 (de) | Pulverförmige formulierungen von grenzflachenaktiven substanzen auf festen, wasserlöslichen tragern, verfahren zu deren herstellung sowie deren verwendung | |
EP1984302A1 (de) | Verfahren zur herstellung von lithium-molybdat nanopartikeln | |
DE3536902A1 (de) | Verfahren zur mikrokapselung durch phasentrennung von wasserloeslichen arzneimittelsubstanzen | |
DE3115080A1 (de) | Arzneimittel fuer die orale verabreichung und verfahren zu seiner herstellung | |
DE102009042037A1 (de) | Herstellung ECM-analoger Matrizen mittels 2-Photonen-Polymerisation | |
EP0490193A1 (de) | Komplexe des aktiven Enantiomers des Ibuprofens mit Cyclodextrin | |
DE102005041570A1 (de) | Hoch verzweigte Reagenzien zur Modifaktion von Biopharmazeutika, deren Herstellung und Anwendung | |
EP3624853A1 (de) | Freisetzung von wirkstoffen unter verwendung siliconhaltiger polymere | |
WO2014037429A2 (de) | Verfahren zur herstellung eines polyglycerin-nanogels zur verkapselung und freisetzung biologisch aktiver substanzen | |
CN1883265A (zh) | 一种杀钉螺药物氯硝柳胺乙醇胺盐纳米悬浮剂及其制备方法 | |
EP1099468A2 (de) | Mikroporöse hydrophile Membran | |
DE2830901C2 (de) | Reaktionsprodukte von Methotrexat und Divinyläther-Maleinsäureanhydrid- copolymerisaten, Verfahren zu ihrer Herstellung und ihre Verwendung | |
DE3421860C2 (de) | Verfahren zum Überziehen von Arzneiformen | |
DE2736036A1 (de) | Nicht-toxische polymere, verfahren zu deren herstellung und daraus hergestellte arzneimittel | |
EP1211942B1 (de) | Verfahren zur herstellung von polyvinylpyrrolidon-iod in wässriger lösung | |
DE69920039T2 (de) | Quinapril magnesium enthaltende, pharmazeutisch wirksame zusammensetzung | |
EP0394731A1 (de) | Verfahren zur Herstellung von Mischungen aus Xanthan und Cellulosederivaten | |
DE1944693B2 (de) | Pharmazeutische zubereitung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20191022 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C08G 77/388 20060101ALI20200603BHEP Ipc: A61K 47/34 20170101AFI20200603BHEP Ipc: A61K 9/70 20060101ALI20200603BHEP |
|
INTG | Intention to grant announced |
Effective date: 20200708 |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20201119 |